IJCCM
 

REVIEW ARTICLE
[Download PDF
 
Year : 2005  |  Volume : 9  |  Issue : 1  |  Page : 47-51  

Hyponatremia in neurological diseases in ICU

Rahul Lath 
 Department of Neurosurgery, Apollo Hospitals, Jubilee Hills, Hyderabad - 500 033, India

Correspondence Address:
Rahul Lath
Department of Neurosurgery, Apollo Hospitals, Jubilee Hills, Hyderabad - 500 033
India

Abstract

Hyponatremia is the commonest electrolyte disturbance encountered in the neurological and neurosurgical intensive care units. It can present with signs and symptoms mimicking a neurological disease and can worsen the existing neurological deficits. Hyponatremia in neurological disorders is usually of the hypo-osmolar type caused either due to the Syndrome of Inappropriate Secretion of Anti Diuretic Hormone (SIADH) or Cerebral Salt Wasting Syndrome (CSWS). It is important to distinguish between these two disorders, as the treatment of the two differ to a large extent. In SIADH, the fluid intake is restricted, whereas in CSWS the treatment involves fluid and salt replacement.



How to cite this article:
Lath R. Hyponatremia in neurological diseases in ICU.Indian J Crit Care Med 2005;9:47-51


How to cite this URL:
Lath R. Hyponatremia in neurological diseases in ICU. Indian J Crit Care Med [serial online] 2005 [cited 2014 Oct 2 ];9:47-51
Available from: http://www.ijccm.org/text.asp?2005/9/1/47/16270


Full Text

 Introduction



Hyponatremia is a common electrolyte disorder encountered in patients in the neurological and neurosurgical ICU.[1],[2],[3],[4],[5] The neurological disorders that cause hyponatremia are diverse and include neurotrauma, subarachnoid hemorrhage, intracerebral hemorrhage, meningitis and stroke. It can occur in the post-operative neurosurgical patient, especially those undergoing surgery in the pituitary/hypothalamic region.[1],[6],[7] Hyponatremia occurring in disorders of the nervous system is either due to the Syndrome of Inappropriate Secretion of Anti Diuretic Hormone (SIADH) or Cerebral Salt Wasting Syndrome (CSWS).[1],[2],[3],[4],[5],[6],[7],[8] It is important to distinguish between these two conditions as the treatment of the two differ. The treatment in SIADH involves fluid restriction, while in CSWS, fluid and salt replacement is the mainstay of treatment. Hyponatremia in neurological disorders may be acute or become chronic.

 Basic Physiology



Sodium plays a vital role in maintaining the concentration and volume of the extracellular fluid (ECF). It is the main cation of the ECF and a major determinant of ECF osmolality. Sodium is important in maintaining irritability and conduction of nerve and muscle tissues and assists in the regulation of acid-base balance. The average daily sodium intake far exceeds the normal daily requirement. The kidneys are responsible for excreting the excess and are capable of conserving sodium during periods of extreme sodium restriction. The kidneys accomplish this primarily through regulation of water intake/excretion. If the serum sodium concentration falls, kidneys respond by excreting water. If the serum sodium increases (increased osmolality), thirst center is stimulated with subsequent ADH release by the posterior pituitary which acts on kidneys to conserve water. Aldosterone also plays a key role by regulating Na+/ECF volume. Its release causes the kidneys to conserve water and sodium which results in increased ECF volume. As changes in serum sodium levels typically reflect changes in body water balance, gains or losses of total body sodium are not necessarily reflected by the serum sodium level. The normal serum sodium level is 135-145 milli equivalents per litre (meq/l). Patients with a serum sodium concentration less than 135 meq/l are considered to be hyponatremic.

 Clinical presentation



The clinical manifestations of hyponatremia are more evident when the decrease in serum sodium concentration is large or when the decrease occurs over a short period of time.[9] Patients in whom the serum sodium concentration is greater than 130 meq/l are usually asymptomatic, whereas those in whom these values are lower may have symptoms that include headache, nausea, vomiting, muscle cramps, lethargy, restlessness, disorientation, and depressed reflexes. Severe and rapidly evolving hyponatremia may present with seizures, coma, permanent brain damage, respiratory arrest, brainstem herniation, and death.[9]

 Categories of Hyponatremia



It can be subdivided into hyponatremia associated with high, normal, or low serum osmolality.[6],[10]

Hyperosmolar hyponatremia: In hyperosmotic hyponatremia, solutes confined to the extracellular compartment induce shifts in transcellular water. Conditions causing hyperosmotic hyponatremia include hyperglycemia and the retention of hypertonic mannitol which results in hyponatremia because water shifts from the intracellular to the extracellular space, causing dehydration of cells.

Iso-osmolar hyponatremia: Isosmotic hyponatremia occurs in patients who undergo transurethral resection of the prostate or hysterectomy. During these procedures, patients may absorb large quantities of hyposmotic glycine or sorbitol irrigating solutions leading to a dilutional reduction in the plasma sodium concentration. A less common condition of hyponatremia associated with normal serum osmolality is seen in patients with extreme hyperlipidemia and hyperproteinemia which is also known as pseudohyponatremia.

Hypo-osmolar hyponatremia: Most hyponatremic disorders are associated with hyposmolality. This subcategory of hyponatremia may be further differentiated according to the volume status:

1. Volume-expanded hyponatremia occurs when the intake of salt and water exceeds renal and extrarenal losses.

a. Disorders associated with interstitial fluid shift include congestive heart failure, nephrotic syndrome, cirrhosis, renal failure (acute and chronic), pregnancy and sepsis.

b. Disorders associated with limited interstitial fluid shift are Syndrome of inappropriate ADH secretion (SIADH), hypothyroidism, adrenal insufficiency, primary polydipsia and cancers.

2. Volume-contracted hyponatremia is mainly caused by fluid loss from the intravascular space, which is induced by an intrinsic or a secondary renal loss of sodium, an extrarenal loss of sodium or hypokalemia. The causes include Cerebral Salt Wasting Syndrome (CSWS), hypokalemia, renal disorders producing sodium loss and extrarenal sodium loss like in vomiting and diarrhoea.

The hyponatremia encountered in neurological intensive care is most frequently of the hypo-osmolar type and the two common diagnoses are SIADH and CSWS.[1],[2],[3],[4],[5],[6],[7],[8] It is important to distinguish between SIADH and CSWS because the treatment differs to a large extent between the two conditions. The SIADH is a volume-expanded condition, whereas CSWS is a volume-contracted state that involves renal loss of sodium. Treatment for patients with SIADH is fluid restriction and treatment for patients with CSWS is generally salt and water replacement. The clinical and laboratory differences between SIADH and CSWS are summarized in [Table 1].

 SIADH



In SIADH there is excessive release of ADH in response to intracranial disease, drug-induced pituitary release of ADH or the ectopic production of ADH.[10] This leads to fluid retention with expansion of the extracellular fluid volume leading to a dilutional hyponatremia and elevation of urine osmolality. For reasons that are unclear, edema does not occur. Currently, the physiological conditions behind the increased urinary sodium concentrations associated with SIADH is not understood, although natriuresis associated with SIADH has been attributed to an increase in the glomerular filtration rate and/or a decrease in renal tubular sodium resorption, which is induced by either hormonal or direct neural effects. The diagnostic criteria for SIADH[10] include

1. hyponatremia

2. low serum osmolality (18 meq/l)

4. high ratio of urine:serum osmolality, often 2:1 or more

5. normal renal, adrenal and thyroid function

6. normal serum potassium and acid base balance

 CSWS



The mechanism by which intracranial disease leads to CSWS is not well understood. The postulated mechanisms include, disruption of neural input into the kidney or the central elaboration of a circulating natriuretic factor or both.[11],[12] Decreased sympathetic input to the kidney directly and indirectly alters salt and water management and may explain the natriuresis and diuresis seen within CSWS. A decrease in sympathetic tone leads to a decreased glomerular filtration rate, a decreased renin release, and a decreased renal tubular sodium resorption. In addition to a decreased neural input to the kidney, an ouabain-like compound in the brain may play a role in renal salt wasting.

The natriuretic factors that play a role in CSWS include the Atrial Natriuretic Peptide (ANP) and Brain Natriuretic Peptide (BNP).[13],[14],[15],[16] ANP is released from the heart in response to atrial stretch and induces vasodilation as well as natriuresis and diuresis. BNP is secreted by the cardiac ventricles in response to increased pressure or stretch and displays biological effects similar to those of ANP.

The electrolyte imbalances observed in CSWS are similar to that of SIADH; however, the presence of signs of volume depletion (decreased skin turgor, hypotension, or low central venous pressure) with salt wasting distinguishes CSWS from SIADH. Additional laboratory evidence that relates to the Extracellular Volume (ECV) may also help distinguish SIADH from CSWS. These include hemoconcentration, albumin concentration, blood urea nitrogen/creatinine ratio, potassium concentration, atrial natriuretic factor, plasma urea concentration and central venous pressure. [Table 1]

 Diagnostic Workup



The goals of investigations[17] in a hyponatremic patient in the neurological ICU are to establish:

1. Serum Osmolality and Urine Osmolality

2. Assessment of Volume status: This can be assessed by measurement of the Central Venous Pressure (CVP), Pulmonary Capillary Wedge Pressure (PCWP) or by radioisotope scanning.

3. Documentation of Renal sodium loss: Urine Spot Sodium

4. Routine blood investigations which include blood sugars, serum creatinine, blood urea, uric acid.

5. To rule out hypothyroidism and adrenal insufficiency (especially in severe head injury and post operative patients undergoing hypothalamic/pituitary surgery).

 Management of Hyponatremia



Once the distinction between SIADH and CSWS has been made, the management is summarized in [Figure 1].

SIADH: If the SIADH occurs in an acute setting then the treatment involves fluid restriction to 1 litre per day.[10],[18] If anemia is the cause of SIADH then correct the anemia with blood transfusion. If the hyponatremia is severe then hypertonic saline (3% - 513 meq/l) should be used and concomitant Furosemide may be used to prevent fluid overload. If the SIADH is chronic then long term fluid restriction to 1.2-1.5 litres per day is advised. Drugs used for the treatment of chronic SIADH include demeclocycline, lithium, phenytoin and furosemide.

CSWS: The treatment of CSWS involves hydration of the patient with normal saline (0.9% NaCl) and oral salt replacement.[1],[4],[8],[11],[12] If the hyponatremia is very severe then 3% saline may be used. Fludrocortisone acetate in the doses of 0.2 mg via intravenous or oral route has been used for the treatment of CSWS.[19] It acts on the renal tubules and increases sodium absorption. However, it can cause complications like pulmonary edema, hypertension and hypokalemia.

Calculation of Sodium Deficit = 0.6 x (weight in kg) x (Desired sodium - Actual sodium). Use 0.5 for females. Desired sodium range = 125-130 meq/l.

Rate of correction of hyponatremia: When hyponatremia is symptomatic and acute (<24 hours in duration), the serum sodium may be raised safely to 120-125 meq/l in 24 hours or less. In patients with symptomatic chronic hyponatremia, or hyponatremia of unknown duration, the serum sodium should be raised slowly (0.5 meq/l/hr) to about 120-125 meq/l in order to avoid central nervous system complications (cerebral edema, pontine myelinolysis, seizures) and/or pulmonary edema. The total increase in these patients should not exceed 10-12 meq/l in 24 hours or <20-25 meq/l over 48 hours.[10]

 Conclusions



Hyponatremia in the neurological intensive care unit is usually of the hypo-osmolar type and is attributable to either SIADH or CSWS. It is crucial to distinguish between these two disorders as the treatment is diametrically opposite. The treatment in SIADH involves fluid restriction while in CSWS fluid and salt replacement are essential.

References

1Sivakumar V, Rajshekhar V, Chandy MJ. Management of neurosurgical patients with hyponatremia and natriuresis. Neurosurgery 1994;34:269-74.
2Coenraad MJ, Meinders AE, Taal JC, Bolk JH. Hyponatremia in intracranial disorders. Neth J Med 2001;58:123-7.
3Bussmann C, Bast T, Rating D. Hyponatraemia in children with acute CNS disease: SIADH or cerebral salt wasting? Childs Nerv Syst 2001;17:58-62.
4Palmer BF. Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends Endocrinol Metab 2003;14:182-7.
5Rabinstein AA, Wijdicks EF. Hyponatremia in critically ill neurological patients. Neurologist 2003;9:290-300.
6Cole CD, Gottfried ON, Liu JK, Couldwell WT. Hyponatremia in the neurosurgical patient: Diagnosis and management. Neurosurg Focus 2004;16:E9.
7Casulari LA, Costa KN, Albuquerque RC, Naves LA, Suzuki K, Domingues L. Differential diagnosis and treatment of hyponatremia following pituitary surgery. J Neurosurg Sci 2004;48:11-8.
8Pamler BF. Hyponatraemia in a neurosurgical patient: Syndrome of inappropriate antidiuretic hormone secretion versus cerebral salt wasting. Nephrol Dial Transplant 2000;15:262-8.
9Adroguι HJ, Madias NE. Hyponatremia: Review. N Engl J Med 2000;342:1581-9.
10Singer GG, Brenner BM. Fluid and electrolyte disturbances. In: Harrisons Principles of Internal Medicine. 16th Ed, Vol 1. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. New York: McGraw Hill; 2005. p. 252-63.
11Harrigan MR. Cerebral salt wasting syndrome: A review. Neurosurgery 1996;38:152-60.
12Harrigan MR. Cerebral salt wasting syndrome. Crit Care Clin 2001;17:125-38.
13Berendes E, Walter M, Cullen P, Prien T, Van Aken H, Horsthemke J, et al. Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet 1997;349:245-9.
14Wijdicks EF, Schievink WI, Burnett JC Jr. Natriuretic peptide system and endothelin in aneurysmal subarachnoid hemorrhage. J Neurosurg 1997;87:275-80.
15Isotani E, Suzuki R, Tomita K, Hokari M, Monma S, Marumo F, et al. Alterations in plasma concentrations of natriuretic peptides and antidiuretic hormone after subarachnoid hemorrhage. Stroke 1994;25:2198-203.
16Narotam PK, Kemp M, Buck R, Gouws E, van Dellen JR, Bhoola KD. Hyponatremic natriuretic syndrome in tuberculous meningitis: The probable role of atrial natriuretic peptide. Neurosurgery 1994;34:982-8.
17Milionis HJ, Liamis GL, Elisaf MS. The hyponatremic patient: A systematic approach to laboratory diagnosis. Review. CMAJ 2002;166:1052-62.
18Robertson GL. Disorders of Neurohypophysis. In: Harrisons Principles of Internal Medicine. 16th Ed, Vol 2. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. New York: McGraw Hill; 2005. p. 2097-104.
19Hasan D, Lindsay KW, Wijdicks EF, Murray GD, Brouwers PJ, Bakker WH, et al. Effect of fludrocortisone acetate in patients with subarachnoid hemorrhage. Stroke 1989;20;1156-61.